Arbutus Biopharma (ABUS) Cash from Investing Activities (2013 - 2026)

Arbutus Biopharma (ABUS) has reported Cash from Investing Activities for 14 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• Quarterly Cash from Investing Activities fell 80.62% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (down 71.55% YoY) and the FY2025 annual result came in at $15.6 million, down 32.11% from the prior year.
• Cash from Investing Activities advanced to $2.2 million in Q1 2026 per ABUS's latest filing, from -$1.4 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for ABUS reached as high as $22.2 million in Q4 2023 and fell as low as -$60.1 million in Q1 2022.
• A 5-year average of $974000.0 and a median of $9.8 million in 2024 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 429.6% — and 2024, when it surged 582.1%.
• Year by year, Cash from Investing Activities stood at $12.7 million in 2022, then jumped by 75.25% to $22.2 million in 2023, then slumped by 39.66% to $13.4 million in 2024, then plunged by 110.15% to -$1.4 million in 2025, then jumped by 261.57% to $2.2 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $2.2 million, -$1.4 million, and -$10.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.